Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-032: Pembrolizumab in Chinese NSCLC
NCT02835690Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2016
- Primary completion
- Sep 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experienced an Adverse Event, Number of Participants Who Discontinued Study Drug Due to an AE and 7 more. Started Aug 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02835690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02835690.